DNA damage induced by novel demethylcantharidin-integrated platinum anticancer complexes

Biochemical and Biophysical Research Communications

Volumn 363, Issue 1, 2007, Pages 235-240

  Pang, Siu Kwong ^a   Yu, Chun Wing ^a   Au Yeung, Steve C F ^a   Ho, Yee Ping ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Alkaline comet assay; Demethylcantharidin platinum complexes; DNA damage

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; NORCANTHARIDIN; NORCANTHARIDIN PLATINUM COMPLEX; OXALIPLATIN; PLATINUM COMPLEX; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HCT116; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANTHARIDIN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA DAMAGE; DNA, NEOPLASM; HUMANS; PLATINUM;

EID: 34548801852     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.08.172     Document Type: Article

References (26)

1. Wong E., and Giandomenico C.M. Current status of platinum-based antitumor drugs. Chem. Rev. 99 (1999) 2451-2466
2. Raymond E., Faivre S., Chaney S., Woynarowski J., and Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol. Cancer Ther. 1 (2002) 227-235
3. Rajski S.R., and Williams R.M. DNA cross-linking agents as antitumor drugs. Chem. Rev. 98 (1998) 2723-2795
4. Blommaert F.A., Van Dijk-Knijmemburg H.C.M., Dijt F.J., den Engelse L., Baan R.A., Berends F., and Fichtinger-Schepman A.M.J. Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. Biochemistry 34 (1995) 8474-8480
5. Stojic L., Brun R., and Jiricny J. Mismatch repair and DNA damage signaling. DNA Repair 3 (2004) 1091-1101
6. Woynarowski J.M., Chapman W.G., Napier C., Herzig M.C.S., and Juniewicz P. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol. Pharmacol. 54 (1998) 770-777
7. Brabec V., and Kasparkova J. Modifications of DNA by platinum complexes: relation to resistance of tumors to platinum antitumor drugs. Drug Resist. Updat. 8 (2005) 131-146
8. Wei M., Cohen S.M., Silverman A.P., and Lippard S.J. Effects of spectator ligands on the specific recognition of intrastrand platinum-DNA cross-links by high mobility group box and TATA-binding proteins. J. Biol. Chem. 276 (2001) 38774-38780
9. Massicot F., Dutertre-Catella H., Pham-Huy C., Liu X.-H., Due H.T., and Warnet J.-M. In vitro assessment of renal toxicity and inflammatory events of two protein phosphatase inhibitors cantharidin and nor-cantharidin. Basic Clin. Pharmacol. 96 (2005) 26-32
10. McCluskey A., Sim A.T.R., and Sakoff J.A. Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies. J. Med. Chem. 45 (2002) 1151-1175
11. Yu C.-W., Li K.K.W., Pang S.-K., Au-Yeung S.C.F., and Ho Y.-P. Anticancer activity of a series of platinum complexes integrating demethylcantharidin with isomers of 1,2-diaminocyclohexane. Bioorg. Med. Chem. Lett. 16 (2006) 1686-1691
12. Efferth T., Rauh R., Kahl S., Tomicic M., Böchzelt H., Tome M.E., Briehl M.M., Bauer R., and Kaina B. Molecular modes of action of cantharidin in tumor cells. Biochem. Pharmacol. 69 (2005) 811-818
13. Au-Yeung S.C.F., Pang P.S.K., and Ho Y.P. Innovative platinum derived anticancer agents-risk or opportunity?. Nat. Rev. Drug Discov. 5 (2006) 5-9 10.1038/nrd1691-c1
14. Tice R.R., Agurell E., Anderson D., Burlinson B., Hartmann A., Kobayashi H., Miyamae Y., Rojas E., Ryu J.-C., and Sasaki Y.F. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ. Mol. Mutagen. 35 (2000) 206-221
15. Darzynkiewicz Z., and Juan G. DNA content measurement for dna ploidy and cell cycle analysis. In: Robinson J.P., Darzynkiewicz Z., Dobrucki J., Hyun W.C., Nolan J.P., Orfao A., and Rabinovitch P.S. (Eds). Current Protocols in Cytometry (2003), John Wiley and Sons Inc. Chapter 7, Unit 7.5
16. Strauss W.M. Preparation of genomic dna from mammalian tissue. In: Ausubel F.M., Brent R., Kingston R.E., Moore D.D., Seidman J.G., Smith J.A., and Struhl K. (Eds). Current Protocols in Molecular Biology (2002), John Wiley & Sons, Inc. Chapter 2, Section I, Unit 2.2
17. L and increases oxaliplatin- and Fas-induced apoptosis. J. Biol. Chem. 279 (2004) 46113-46121
18. Wozniak K., Czechowska A., and Blasiak J. Cisplatin-evoked fragmentation in normal and cancer cells and its modulation by free radical scavengers and tyrosine kinase inhibitor STI571. Chem. Biol. Interact. 147 (2004) 309-318
19. Fairbain D.W., Olive P.L., and O'Neill K.L. The comet assay: a comprehensive review. Mutat. Res. 339 (1995) 37-59
20. Miyamae Y., Iwasaki K., Kinae N., Tsuda S., Murakami M., Tanaka M., and Sasaki Y. Detection of DNA lesions induced by chemical mutagens using the single-cell gel electrophoresis (Comet) assay. Relationship between DNA migration and alkaline condition. Mutat. Res. 393 (1997) 107-113
21. Takagi K., Kawai Y., Yamauchi T., and Ueda T. Inhibition of repair of carboplatin-induced DNA damage by 9-β-d-arabinofuranosyl-2-fluoroadenine in quiescent human lymphocytes. Biochem. Pharmacol. 68 (2004) 1757-1766
22. Kok S.H., Hong C.Y., Kuo M.Y.P., Lee C.H.K., Lee J.J., Lou I.U., Lee M.S., Hsiao M., and Lin S.K. Comparisons of norcantharidin cytotoxic effects on oral cancer cells and normal buccal keratinocytes. Oral Oncol. 39 (2003) 19-26
23. Kok S.-H., Cheng S.-J., Hong C.-Y., Lee J.-J., Lin S.-K., Kuo Y.-S., Chiang C.-P., and Kuo M.Y.-P. Norcantharidin-induced apoptosis in oral cancer cells is associated with an increase of proapoptotic to antiapoptotic protein ratio. Cancer Lett. 217 (2005) 43-52
24. Li J.-L., Cai Y.-C., Liu X.-H., and Xian L.-J. Norcantharidin inhibits DNA replication and induces apoptosis with the cleavage of initiation protein Cdc6 in HL-60 cells. Anticancer Drug 17 (2006) 307-314
25. Boyer J., McLean E.G., Aroori S., Wilson P., McCulla A., Carey P.D., Longley D.B., and Johnston P.G. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin. Cancer Res. 10 (2004) 2158-2167
26. Rakitina T.V., Vasilevskaya I.A., and O'Dwyer P.J. Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor κB signaling. Cancer Res. 63 (2003) 8600-8605